Resolving sex and gender bias in COVID-19 vaccines R&D and beyond
- PMID: 35143380
- PMCID: PMC9009935
- DOI: 10.1080/21645515.2022.2035142
Resolving sex and gender bias in COVID-19 vaccines R&D and beyond
Abstract
The influence of sex and gender in immune response and vaccine outcomes is established in many disease areas, including in COVID-19. Yet, there are notable gaps in the consideration of sex and gender in the analysis and reporting of COVID-19 vaccines clinical trial data. The push for stronger sex and gender integration in vaccines science should be championed by all researchers and stakeholders across the R&D and access ecosystem - not just gender experts. This requires joint action on the tactical framing of customized value propositions (based on stakeholder motivations), the stronger enforcement of existing regulation, tools, and commitments, and aligning the overall agenda to parallel calls on intersectionality, equity diversity and inclusion.
Keywords: COVID-19; gender; sex; vaccines research.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
References
-
- Ursin RL, Klein SL.. Sex differences in respiratory viral pathogenesis and treatments. Annu Rev Virol [Internet]. 2021;8:393–3. [accessed 2021 Jul 2]. https://www.annualreviews.org/doi/ 10.1146/annurev-virology-091919-092720. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical